chromatographies were carried out with silica gel (60 Å pore size, 230-400 mesh particle size) from Sigma Aldrich as a stationary phase, while preparative HPLC purifications were conducted on a MerckHitachi system (D-7000 interface, L-7400 UV detector and L-7100 pump) with a Ultimate XB-C18 reversed-phase column (5 µm, 21.2 x 150 mm), using a mixture of aqueous NH4HCO3 (10 mM, solvent 1 H and 13 C nuclear magnetic resonance (NMR) spectra were recorded at ambient temperature on a Bruker Avance FT-NMR (400 MHz) using CDCl3 as a solvent. Chemical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane (0.00 ppm) with the respective solvent signals as internal standard (δH = 7.26 ppm and δC = 77.16 for CDCl3). 1 H-NMR spectra resonance multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, m = multiplet, dd = doublet of doublet, and br = broad peak, whereas coupling constants (J) are given in hertz (Hz). High resolution mass spectrometry (HRMS) was carried out on a Bruker maXis -ESI-Qq-TOF-MS spectrometer and the corresponding mass/charge (m/z) ratios are given in atom mass units. Binding affinities of OF-Me-NB1
and PF-Me-NB1 were determined as previously reported (1).
Supplemental Figure 1:
Synthesis of reference compounds OF-Me-NB1 and PF-Me-NB1 as well as the respective phenolic precursors OF-NB1 and PF-NB1. Chiral separation was carried out by semipreparative HPLC under isochratic normal phase conditions using a system of hexane/isopropanol (4:1). 
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3-(4-(2-fluorophenyl)butyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-1,7-diol (OF-NB1)
To a solution of OF-Me-NB1 (84 mg, 0.25 mmol) in DCM (3.6 mL) was added dropwise BBr3 (1M in DCM, 1.8 mL, 1.80 mmol) at -78 °C. Upon stirring for 1h at ambient temperature, the mixture was quenched with aq. NaOH (1 mM) and the pH adjusted to 7 using aq. NaOH (5 M). Volatiles were evaporated under reduced pressure and the resulting brown solid washed by trituration with water. The crude residue was purified by HPLC to afford OF-NB1 (33 mg, 0.10 mmol, 41 % yield 
3-(4-(4-fluorophenyl)butyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1,7-diol (PF-NB1)
To a solution of PF-Me-NB1 (118 mg, 0.343 mmol) in DCM (5 ml) was added dropwise a solution of BBr3 in DCM (1M, 2.5 ml, 2.50 mmol) at -78 °C. The reaction mixture was stirred for 3.5h at ambient temperature and subsequently quenched by addition of ice water. Volatiles were removed under reduced pressure and the aqueous phase alkalized with aq. NaOH (1M). The mixture was extracted with ethyl acetate (3x 150 mL) and the combined organic layers were concentrated under reduced pressure. 
Radiochemistry (Carbon-11 Labeling)
Carbon-11 labeling was performed as previously reported (1). Briefly, [ 
of (R)-and (S)-PF-NB1 as well as (R)-and (S)-OF-NB1.

Synthesis of Precursor 7 for Radiofluorination
Supplemental Figure 4 : Synthesis of aryl boronic ester precursor 7 for radiofluorination. Chiral resolution was performed by semipreparative HPLC.
The synthesis of compound 3 and 4 were performed according to published procedure (2).
3-(4-(2-iodophenyl)butyl)-7-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol (5)
To a mixture of 4-(2-iodophenyl)butan-1-ol (340 mg, 1.23 mmol) and Et3N (224 mg, 2.21 mmol) in DCM (12.4 mL) was added dropwise mesyl chloride (137 mg, 1.20 mmol) at 0 °C. The mixture was stirred for 1h at ambient temperature, subsequently diluted with water (10 mL) and extracted with DCM 
3-(4-(2-iodophenyl)butyl)-7-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl acetate (6)
DMAP (9 mg, 0.07 mmol), Et3N (76 mg, 0.75 mmol), acetic anhydride (76 mg, 0.74 mmol) and benzazepine 5 (165 mg, 0.37 mmol) were dissolved in DCM (8.8 mL). After stirring for 8.5h at ambient temperature, the mixture was diluted with sat. NaHCO3 and extracted with DCM (3 x 100 mL).
Combined organic layers were back-extracted with brine, dried over MgSO4 and volatiles were removed under reduced pressure. The crude residue was purified by flash column chromatography (hexane/ethyl acetate 7:3) to afford the title compound (110 mg, 0.22 mmol, 61% yield). 
7-methoxy-3-(4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butyl)-2,3,4,5-tetra-hydro-1H-benzo[d]azepin-1-yl acetate (7)
Compound 6 (102 mg, 0.21 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (65 mg, 0.26 mmol), potassium acetate (81 mg, 0.83 mmol) and Pd(dppf)Cl2DCM (8 mg, 0.011 mmol) were combined in one flask and dissolved in DMF (2.1 mL). After stirring for 5 h at 100 °C, the mixture was diluted with water (10 mL) and extracted with MTBE (3 x 40 mL). Combined organic layers were backextracted with brine, dried over MgSO4 and volatiles were evaporated under reduced pressure. In vitro autoradiography (carbon-11 labeled probes) to assess GluN2B-specficity and selectivity over the σ1R.
Determination of Distribution Coefficient at pH 7.4
The distribution coefficient of (R)-[ 
Receptor Occupancy Calculations
Receptor occupancy studies with GluN2B-antagonist CP101,606 were conducted using bolus injections of doses ranging from 0.1 mg/kg up to 10 mg/kg. Receptor occupancy was calculated from the applied blocker dose and the respective time-activity curves (area under the curve) according to equations 1 and 2 (4). 
Ex vivo biodistribution Supplemental
